IPO - CONDUIT PHARMACEUTICALS INC.

Form Type: CORRESP

Filing Date: 2024-12-04

Corporate Action: Ipo

Type: New

Accession Number: 000149315224048645

Filing Summary: Conduit Pharmaceuticals Inc. has submitted a request to the U.S. Securities and Exchange Commission to expedite the effectiveness of its Registration Statement on Form S-3, filed under File No. 333-283449. The company requests that the Registration Statement be declared effective on December 6, 2024, at 4:30 p.m. Eastern Time or as soon as practicable thereafter. The correspondence was made by David Tapolczay, the CEO of Conduit Pharmaceuticals, and includes contact details for their legal counsel, Todd Mason, for any follow-up inquiries or confirmations regarding the effectiveness of the Registration Statement.

Document Link: View Document